



**PATENT**  
Attorney Docket No. Hys-5

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicant(s):** Boyle, *et al.*  
**Serial No:** 09/545,283  
**Filed:** April 7, 2000  
**For:** **METHODS AND MATERIALS  
RELATING TO NOVEL C-TYPE  
LECTIN RECEPTOR-LIKE  
POLYPEPTIDES AND  
POLYNUCLEOTIDES**  
**Examiner:** Jehanne E. Souaya  
**Group:** 1634

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8**

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to the Mail Stop FEE AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit: April 4, 2003

Type or Print Name of Person Mailing: Donna B. Rose

*Donna B. Rose*  
Signature of Person Mailing

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER**  
**37 CFR 1.58(e)**

Mail Stop FEE AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Applicants state that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the original information disclosure statement.

The Applicants do not believe that the information contained in the Supplemental Information Disclosure Statement discloses information material to the patentability of the application.

04/11/2003 CNGUYEN 00000015 501169 09545283

02 FC:1006 180.00 CH

The Applicants believe that a fee is due for the submission of this Supplemental Information Disclosure Statement. The Commissioner is hereby authorized to charge the amount of \$180.00 and any additional fees due or credit any overpayment to Deposit Account No. 501169. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: April 4, 2003

By: Renee S. Polizotto  
Renee S. Polizotto  
Agent for Applicants  
Registration No. 53,474  
NUVELO  
675 Almanor Avenue  
Sunnyvale, CA 94085  
(408) 215.4000 Telephone  
(408) 524-8145 Facsimile


Form O-1449 (Modified)	U.S. Department of Patent and Trademark	Atty. Docket No. <b>HYS-5</b>	Serial No. <b>09/545,283</b>
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>  <i>(Use several sheets if necessary)</i>		Applicant <b>Boyle, et al.</b>	
		Filing Date <b>04/07/2000</b>	Group <b>1634</b>

U.S. PATENT DOCUMENTS							
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
	C14	Banchereau & Steinman, "Dendritic cells and the control of immunity," Nature 392:245-252 (1998).
	C15	Bates et al., "APCs express DCIR, a novel C-type lectin surface receptor containing an immunoreceptor tyrosine-based inhibitory motif," J. Immunol. 163:1973-1983 (1999).
	C16	Clark et al., "The role of dendritic cells in the innate immune system," Microbes Infect. 2:257-272 (2000).
	C17	Drickamer, "Biology of Lectins," Annu. Rev. Cell Biol. 9:237-264 (1993).
	C18	O'Doherty et al., "Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium," J. Exp. Med. 178:1067-1078 (1993).
	C19	Steinman, "The dendritic cell system and its role in immunogenicity," Annu. Rev. Immunol. 9:271-296 (1991).
	C20	Suphioglu et al., "Mechanism of grass-pollen-induced asthma," Lancet 339:569-572 (1992).
	C21	Wang et al., "Allergen-induced bronchial inflammation is associated with decreased

EXAMINER	DATE CONSIDERED
<b>*EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.	

SHEET 2 of 2

Form PTO-1449 (Modified)

U.S. Department of  
Patent and Trademark

Atty. Docket No.

HYS-5

Serial No.

09/545,283

Applicant

Boyle, et al.

Filing Date

04/07/2000

Group

1634

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT***(Use several sheets if necessary)***OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, etc.)levels of surfactant proteins A and D in a murine model of asthma," Clin. Exp.  
Allergy 31:652-662 (2001).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.